Baxter International (BAX) has just been added to the Russell 2500 Index and the Russell 2500 Value Benchmark, a shift that can draw attention from index tracking funds and increase trading interest.

The inclusion in the Russell 2500 Index and Russell 2500 Value Benchmark comes after a sharp shift in momentum, with Baxter International’s 90 day share price return of 35.86% contrasting with a 1 year total shareholder return that declined 23.30%.

If this kind of turning point has your attention, it can also be a good moment to see what else is setting up in the market using our screener for 40 healthcare AI stocks

After Baxter International’s sharp rebound, the stock still trades at a discount to some fair value estimates while sitting slightly above the average analyst target. Is this a recovery the market is still underpricing, or a level of caution that fits the fundamentals?

Most Popular Narrative: 5% Overvalued

The most followed narrative puts Baxter International’s fair value at $21.54, a touch below the last close of $22.58. This frames the current rebound in a more cautious light.

Ongoing portfolio optimization efforts, including divestitures, cost reductions, and a commitment to eliminate stranded costs by 2027, aim to streamline operations, improve efficiency, and drive net margin improvement, which should be reflected in future earnings growth.

Curious what has to happen between now and 2029 for that fair value to make sense? Revenue growth, margin repair, and a richer future earnings multiple all sit at the core of this storyline, but the exact mix might surprise you.

Result: Fair Value of $21.54 (OVERVALUED)

However, this Baxter International storyline still leans on smooth execution. Profit margin repair and the removal of stranded costs both carry clear execution risk.

Another View: Baxter International On Cash Flows And Ratios

While one widely cited view suggests Baxter International may be about 5% overvalued on a fair value estimate of $21.54, our DCF model indicates a value of $29.34 based on projected cash flows. One method points toward caution, while the other suggests a potential discount, so which set of assumptions appears more realistic to you?

Next Steps

Seeing both concern and optimism around Baxter International in this article, it makes sense to move quickly and test the assumptions for yourself using the 3 key rewards and 1 important warning sign.

Looking for more investment ideas beyond Baxter International?

If Baxter International has you rethinking your watchlist, do not stop here. Use the Simply Wall St Screener to surface other opportunities before the crowd moves on.

• Target potential mispricings by scanning for companies that combine quality fundamentals with attractive valuations using the 41 high quality undervalued stocks.
• Strengthen your income focus by reviewing stocks that pair higher yields with resilient business profiles through the 8 dividend fortresses.
• Dial down portfolio risk by spotting companies with steadier profiles and fewer red flags via the 74 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.